ProQR Therapeutics (PRQR) Cash from Operations (2013 - 2026)
ProQR Therapeutics (PRQR) posted Cash from Operations of 13422598.88 for Q1 2026, up 23.9% sequentially from 17638751.38 in Q4 2025, and up 22.08% YoY from 10995111.25 in Q1 2025.
ProQR Therapeutics (PRQR) Cash from Operations (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported Cash from Operations for 14 years, with the latest figure at 13422598.88 in Q1 2026.
- Quarterly Cash from Operations rose 22.08% year-over-year to 13422598.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58889393.65 (down 34.78% YoY) and the FY2025 annual result came in at 63541643.34, down 52.19% from the prior year.
- Cash from Operations improved to 13422598.88 in Q1 2026 per PRQR's latest filing, from 17638751.38 in the prior quarter.
- Over five years, Cash from Operations peaked at 47812011.35 in Q1 2023 and troughed at 22970886.08 in Q1 2022.
- A 5-year average of 9923371.23 and a median of 13524654.35 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 466.29% in 2022, then surged 308.14% in 2023.
- Over 5 years, Cash from Operations stood at 18194071.27 in 2022, then jumped by 78.88% to 3843257.35 in 2023, then slumped by 234.38% to 12850928.28 in 2024, then plunged by 37.26% to 17638751.38 in 2025, then gained by 23.9% to 13422598.88 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 13422598.88, 17638751.38, and 14303389.04 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -13.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.42 Mn |
| Mar 31, 2026 | -13.42 Mn |
| Dec 31, 2025 | -17.64 Mn |
| Dec 31, 2025 | -17.64 Mn |
| Sep 30, 2025 | -14.30 Mn |
| Sep 30, 2025 | -14.30 Mn |
| Jun 30, 2025 | -13.52 Mn |
| Jun 30, 2025 | -13.52 Mn |
| Mar 31, 2025 | -17.23 Mn |
| Mar 31, 2025 | -17.23 Mn |
| Dec 31, 2024 | -12.85 Mn |
| Dec 31, 2024 | -12.85 Mn |
| Sep 30, 2024 | -6.21 Mn |
| Sep 30, 2024 | -6.21 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Mar 31, 2024 | -16.44 Mn |
| Mar 31, 2024 | -16.44 Mn |
| Dec 31, 2023 | -3.84 Mn |
| Dec 31, 2023 | -3.84 Mn |